Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$12.35
+9.4%
$12.90
$9.81
$63.00
$220.72M1.51129,223 shs607,972 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$5.05
-2.7%
$4.46
$0.73
$6.55
$332.47M0.85252,667 shs257,960 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.53
+0.8%
$2.23
$1.15
$3.29
N/A-0.3684,455 shs66,102 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$0.36
-12.1%
$0.24
$0.15
$1.50
$20.63M1.5324.11 million shs5.80 million shs
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$1.19
-0.8%
$1.33
$0.78
$5.15
$41.32M1.731.03 million shs764,973 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+9.39%+0.65%-1.20%-7.42%-98.39%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-2.70%+6.32%+14.51%+80.36%+92.02%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+0.80%-1.56%+17.13%+24.94%-5.24%
Heatwurx Inc. stock logo
PCSA
Heatwurx
-12.13%-8.30%+79.60%+69.06%-72.72%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-0.83%-1.65%-29.17%+8.18%-66.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$12.35
+9.4%
$12.90
$9.81
$63.00
$220.72M1.51129,223 shs607,972 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$5.05
-2.7%
$4.46
$0.73
$6.55
$332.47M0.85252,667 shs257,960 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.53
+0.8%
$2.23
$1.15
$3.29
N/A-0.3684,455 shs66,102 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$0.36
-12.1%
$0.24
$0.15
$1.50
$20.63M1.5324.11 million shs5.80 million shs
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$1.19
-0.8%
$1.33
$0.78
$5.15
$41.32M1.731.03 million shs764,973 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+9.39%+0.65%-1.20%-7.42%-98.39%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-2.70%+6.32%+14.51%+80.36%+92.02%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+0.80%-1.56%+17.13%+24.94%-5.24%
Heatwurx Inc. stock logo
PCSA
Heatwurx
-12.13%-8.30%+79.60%+69.06%-72.72%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-0.83%-1.65%-29.17%+8.18%-66.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.33
Buy$25.60107.29% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.00
Hold$6.0018.81% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.50
Reduce$5.0097.63% Upside
Heatwurx Inc. stock logo
PCSA
Heatwurx
2.00
Hold$1.00177.70% Upside
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
2.75
Moderate Buy$4.00236.13% Upside

Current Analyst Ratings Breakdown

Latest NERV, RMTI, CBIO, PCSA, and GALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/27/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/2/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$2.00 ➝ $1.00
8/27/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
8/26/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K24,144.25N/AN/A$8.24 per share1.50
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.21 per share12.01($3.67) per shareN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A$0.46 per shareN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$101.49M0.40$0.13 per share9.49$1.01 per share1.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$34.93N/AN/AN/AN/A-106.06%-86.60%N/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$1.481.71N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$11.85M-$2.32N/AN/AN/AN/A-342.36%-243.48%10/29/2025 (Estimated)
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$480K-$0.06N/AN/AN/A-2.38%-6.79%-3.77%11/12/2025 (Estimated)

Latest NERV, RMTI, CBIO, PCSA, and GALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2025Q3 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.11N/AN/AN/AN/AN/A
11/12/2025Q3 2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.04N/AN/AN/A$16.24 millionN/A
11/4/2025Q3 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.35N/AN/AN/AN/AN/A
10/29/2025Q3 2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$0.08N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16-$0.12+$0.04-$0.12N/AN/A
8/14/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95-$0.43+$0.52-$0.43N/AN/A
8/14/2025Q2 2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.05-$0.05N/A-$0.05$16.33 million$16.07 million
8/7/2025Q2 2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$0.23-$0.25-$0.02-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
9.21
9.21
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
1.43
1.43
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
6.15
6.15
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
3.45
3.45
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
0.30
2.89
2.51

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
23.31%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million18.77 millionNo Data
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
964.06 million31.97 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
9N/AN/ANot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
2050.35 million49.14 millionNot Optionable
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
30034.43 million33.19 millionOptionable

Recent News About These Companies

Rockwell Medical promotes Heather Hunter to COO
Rockwell Med Appoints Heather Hunter as COO
Rockwell Medical Tops Q2 EPS View

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$12.35 +1.06 (+9.39%)
As of 10/16/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$5.05 -0.14 (-2.70%)
Closing price 10/16/2025 04:00 PM Eastern
Extended Trading
$5.10 +0.05 (+0.99%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$2.53 +0.02 (+0.80%)
Closing price 10/16/2025 03:59 PM Eastern
Extended Trading
$2.50 -0.03 (-1.38%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$0.36 -0.05 (-12.13%)
Closing price 10/16/2025 04:00 PM Eastern
Extended Trading
$0.35 -0.01 (-3.08%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Rockwell Medical stock logo

Rockwell Medical NASDAQ:RMTI

$1.19 -0.01 (-0.83%)
Closing price 10/16/2025 04:00 PM Eastern
Extended Trading
$1.17 -0.02 (-1.68%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.